BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FP 1097: Phase II data

An open-label, dose-escalation, U.S. Phase II trial in 60 women suffering from urinary incontinence or OAB showed that daily intravaginal FP 1097 met the co-primary endpoints of significantly reducing the incidence of incontinence episodes and...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >